◎ Sugi Atlas

Atlas / Disease / Glomerulonephritis

Glomerulonephritis

disease
On this page

Also known as bright's diseaseglomerular nephritisglomerulonephritis (disease)nephritis of renal glomerulusrenal glomerulus nephritis

Summary

Glomerulonephritis (MONDO:0002462) is a disease (an umbrella term covering 20 Mondo subtypes) with 7 cohort genes (54 GWAS associations across 20 studies) and 47 clinical trials. Top therapeutic interventions include losartan, potassium citrate anhydrous, and basiliximab.

At a glance

  • Umbrella term: 20 Mondo subtypes
  • Cohort genes: 7
  • GWAS associations: 54
  • ClinVar variants: 11
  • Clinical trials: 47

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameglomerulonephritis
Mondo IDMONDO:0002462
MeSHD005921
DOIDDOID:2921
NCITC26784
SNOMED CT36171008
UMLSC0017658
MedGen6616
GARD0006516
Anatomy (UBERON)UBERON:0000074
Is cancer (heuristic)no

Also known as: bright’s disease · glomerular nephritis · glomerulonephritis · glomerulonephritis (disease) · nephritis of renal glomerulus · renal glomerulus nephritis

Data availability: 11 ClinVar variants · 54 GWAS associations (20 studies) · 1 HPO phenotype.

Disease family

An umbrella term covering 20 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › kidney disorder › nephritis › glomerulonephritis

Related subtypes (3): interstitial nephritis, hereditary nephritis, pyelitis

Subtypes (20): acute poststreptococcal glomerulonephritis, membranoproliferative glomerulonephritis, exudative glomerulonephritis, proliferative glomerulonephritis, focal embolic glomerulonephritis, anti-basement membrane glomerulonephritis, diffuse glomerulonephritis, subacute glomerulonephritis, mesangial proliferative glomerulonephritis, immune-complex glomerulonephritis, IgA glomerulonephritis, membranous glomerulonephritis, lupus nephritis, minimal change disease, granulomatosis with polyangiitis, rapidly progressive glomerulonephritis, primary membranoproliferative glomerulonephritis, Pauci-immune glomerulonephritis, immunotactoid glomerulopathy, autoimmune glomerulonephritis

Genetics & variants

GWAS landscape

54 GWAS associations across 20 studies. Top hits map to 27 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs738853193e-17APOL1A0.62
chr22:366555133e-15C0.64
rs92724452e-14HLA-DQA1C0.77
rs1430186901e-13ACAP2C3.29
rs92670921e-13LINC01149G0.57
rs5687642453e-13NKX2-3 - SLC25A28G3.08
rs1855370784e-13MIR3201 - TAFA5G3.15
rs5292175965e-13PEX10G3.13
rs1815463228e-13EPHB3 - MAGEF1A2.35
rs5344243632e-12HNRNPA1P69 - LINC03056G4.1
rs5460997072e-12KLF13G3.58
rs5519194402e-12GPCPD1 - SHLD1C3.98
rs5553048902e-12DUSP23 - FCRL6T3.72
rs5656158852e-12OTOL1 - TOMM22P6C4.27
rs5725734452e-12TPCN2G3.46
rs1169154663e-12CDK14C3.76
rs1920569863e-12LINC02947 - LINC02599C4.47
rs1919127814e-12CHD2C4.11
rs1158249294e-12NRXN1A2.69
rs1898305985e-12RPL6P32 - RNA5SP199T3.05
rs1808431626e-12ADGRL2G4.12
rs5743854627e-12PHYKPLG3.87
rs5576616657e-12DNAJB6 - PTPRN2A4.26
rs1917507519e-12COL6A6C2.93
rs1833438489e-12LINC03122T3
rs1140642241e-11RPH3ALT1.06
rs5709780871e-11TMEM132E - CCT6BA3.09
rs1384960351e-11UCHL1 - Y_RNAC2.32
rs1835100191e-11PRKNT4.08
rs21895471e-11NPM1P11 - THSD7AA2.6

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90651774Liu TY20252,315202,534Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90652159Liu TY20251,927202,534Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90478509Verma A20241,216449,020Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90436407Zhou W20181,033397,602Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90436410Zhou W2018845397,602Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90476113Verma A2024775120,581Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480367Verma A2024775120,581Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90018820Sakaue S2021566475,255A cross-population atlas of genetic associations for 220 human phenotypes.
GCST90478510Verma A2024556450,523Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90726807Kim HI202654543,481Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding2
Tier 2: splice/UTR0
Tier 3: regulatory1
Tier 4: intronic/intergenic47

MAF distribution

BucketVariants
common (>=0.05)6
low_freq (0.01-0.05)1
rare (<0.01)43
unknown0

Functional consequences

ConsequenceCount
intron_variant29
intergenic_variant15
missense_variant2
non_coding_transcript_exon_variant2
unknown1
regulatory_region_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs738853192236265860A>G0.048missense_variantAPOL13e-17Tier 1: coding
chr22:366555130.4253e-15Tier 4: intronic/intergenic
rs9272445632637643C>A,T0.076intron_variantHLA-DQA12e-14Tier 4: intronic/intergenic
rs1430186903195291722C>A,T0missense_variantACAP21e-13Tier 1: coding
rs9267092631446464G>T0.091non_coding_transcript_exon_variantLINC011491e-13Tier 4: intronic/intergenic
rs5687642451099608580G>A0.001intron_variantNKX2-3 - SLC25A283e-13Tier 4: intronic/intergenic
rs1855370782248306537G>A0intergenic_variantMIR3201 - TAFA54e-13Tier 4: intronic/intergenic
rs52921759612409902G>A0.001intron_variantPEX105e-13Tier 4: intronic/intergenic
rs1815463223184595806A>G0.001intron_variantEPHB3 - MAGEF18e-13Tier 4: intronic/intergenic
rs5344243631263273718G>A0intergenic_variantHNRNPA1P69 - LINC030562e-12Tier 4: intronic/intergenic
rs5460997071531367861G>A0intron_variantKLF132e-12Tier 4: intronic/intergenic
rs551919440205666226C>T0intergenic_variantGPCPD1 - SHLD12e-12Tier 4: intronic/intergenic
rs5553048901159782750T>C0.001intergenic_variantDUSP23 - FCRL62e-12Tier 4: intronic/intergenic
rs5656158853162405608C>A,T0intergenic_variantOTOL1 - TOMM22P62e-12Tier 4: intronic/intergenic
rs5725734451169064069G>A,T0intron_variantTPCN22e-12Tier 4: intronic/intergenic
rs116915466791137316C>G0intron_variantCDK143e-12Tier 4: intronic/intergenic
rs192056986848524020C>T0.001intergenic_variantLINC02947 - LINC025993e-12Tier 4: intronic/intergenic
rs1919127811592973122C>A,G,T0intron_variantCHD24e-12Tier 4: intronic/intergenic
rs115824929250050221A>G0.001intron_variantNRXN14e-12Tier 4: intronic/intergenic
rs1898305985155707465T>C0.001intergenic_variantRPL6P32 - RNA5SP1995e-12Tier 4: intronic/intergenic
rs180843162181708213G>A0intron_variantADGRL26e-12Tier 4: intronic/intergenic
rs5743854625178214193G>A,C0intron_variantPHYKPL7e-12Tier 4: intronic/intergenic
rs5576616657157454149A>C0intergenic_variantDNAJB6 - PTPRN27e-12Tier 4: intronic/intergenic
rs1917507513130583918C>T0intron_variantCOL6A69e-12Tier 4: intronic/intergenic
rs183343848561793288T>C0intron_variantLINC031229e-12Tier 4: intronic/intergenic
rs11406422417263802T>C,G0.006intron_variantRPH3AL1e-11Tier 4: intronic/intergenic
rs5709780871734651003A>G0.001intergenic_variantTMEM132E - CCT6B1e-11Tier 4: intronic/intergenic
rs138496035441301210C>T0.002intergenic_variantUCHL1 - Y_RNA1e-11Tier 4: intronic/intergenic
rs1835100196162182975T>C0intron_variantPRKN1e-11Tier 4: intronic/intergenic
rs2189547711258923A>C,T0.001intron_variantNPM1P11 - THSD7A1e-11Tier 4: intronic/intergenic

ClinVar germline variants

11 retrieved; paginated sample, class counts are floors:

4 uncertain significance, 4 conflicting classifications of pathogenicity, 2 conflicting classifications of pathogenicity; risk factor, 1 pathogenic

ClinVarVariant (HGVS)GeneClassificationReview
550471NM_000092.5(COL4A4):c.2638del (p.Ala880fs)COL4A4Pathogeniccriteria provided, multiple submitters, no conflicts
127198NM_003661.4(APOL1):c.1152T>G (p.Ile384Met)APOL1Conflicting classifications of pathogenicity; risk factorcriteria provided, conflicting classifications
277678NM_003661.4(APOL1):c.1024A>G (p.Ser342Gly)APOL1Conflicting classifications of pathogenicity; risk factorcriteria provided, conflicting classifications
930185NM_000092.5(COL4A4):c.854G>A (p.Gly285Glu)COL4A4Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
930186NM_000092.5(COL4A4):c.788C>G (p.Pro263Arg)COL4A4Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
930187NM_000092.5(COL4A4):c.1246C>G (p.Pro416Ala)COL4A4Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
499790NM_002473.6(MYH9):c.5185G>T (p.Ala1729Ser)MYH9Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
1210229NM_022489.4(INF2):c.2054T>C (p.Ile685Thr)INF2Uncertain significancecriteria provided, multiple submitters, no conflicts
930193NM_002292.4(LAMB2):c.4307G>A (p.Arg1436His)LAMB2Uncertain significancecriteria provided, multiple submitters, no conflicts
930197NM_004646.4(NPHS1):c.2344G>A (p.Glu782Lys)NPHS1Uncertain significancecriteria provided, multiple submitters, no conflicts
930200NM_016341.4(PLCE1):c.756G>T (p.Gln252His)PLCE1Uncertain significancecriteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 14 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
PLCE1Orphanet:656Hereditary steroid-resistant nephrotic syndrome
COL4A4Orphanet:653722Digenic Alport syndrome
COL4A4Orphanet:88918Autosomal dominant Alport syndrome
COL4A4Orphanet:88919Autosomal recessive Alport syndrome
INF2Orphanet:656Hereditary steroid-resistant nephrotic syndrome
INF2Orphanet:93114Autosomal dominant intermediate Charcot-Marie-Tooth disease type E
APOL1Orphanet:656Hereditary steroid-resistant nephrotic syndrome
LAMB2Orphanet:2670Pierson syndrome
LAMB2Orphanet:98915Synaptic congenital myasthenic syndrome
MYH9Orphanet:182050MYH9-related syndromic thrombocytopenia
MYH9Orphanet:477742Nodular fasciitis
MYH9Orphanet:90635Rare autosomal dominant non-syndromic sensorineural deafness type DFNA
NPHS1Orphanet:656Hereditary steroid-resistant nephrotic syndrome
NPHS1Orphanet:839Congenital nephrotic syndrome, Finnish type

Cohort genes → proteins

7 cohort genes, 7 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence7

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
PLCE1HGNC:17175ENSG00000138193Q9P2121-phosphatidylinositol 4,5-bisphosphate phosphodiesterase epsilon-1clinvar
COL4A4HGNC:2206ENSG00000081052P53420Collagen alpha-4(IV) chainclinvar
INF2HGNC:23791ENSG00000203485Q27J81Inverted formin-2clinvar
APOL1HGNC:618ENSG00000100342O14791Apolipoprotein L1clinvar
LAMB2HGNC:6487ENSG00000172037P55268Laminin subunit beta-2clinvar
MYH9HGNC:7579ENSG00000100345P35579Myosin-9clinvar
NPHS1HGNC:7908ENSG00000161270O60500Nephrinclinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
PLCE11-phosphatidylinositol 4,5-bisphosphate phosphodiesterase epsilon-1The production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is mediated by activated phosphatidylinositol-specific phospholipase C enzymes.
COL4A4Collagen alpha-4(IV) chainType IV collagen is the major structural component of glomerular basement membranes (GBM), forming a ‘chicken-wire’ meshwork together with laminins, proteoglycans and entactin/nidogen.
INF2Inverted formin-2Severs actin filaments and accelerates their polymerization and depolymerization.
APOL1Apolipoprotein L1May play a role in lipid exchange and transport throughout the body.
LAMB2Laminin subunit beta-2Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components.
MYH9Myosin-9Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as secretion and capping.
NPHS1NephrinSeems to play a role in the development or function of the kidney glomerular filtration barrier.

Protein-family classification

Druggable: 2 · Difficult: 1 · Unknown: 4 · Druggable fraction: 0.29

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Antibody/Immunoglobulin14.2×0.609
Scaffold/PPI12.5×0.609
Enzyme (other)11.7×0.609
Other/Unknown41.0×0.626

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
PLCE1Enzyme (other)yes3.1.4.11C2_dom, RA_dom, PLipase_C_PInositol-sp_X_dom
COL4A4Other/UnknownnoCollagen_IV_NC, Collagen, CTDL_fold
INF2Other/UnknownnoWH2_dom, FH3_dom, GTPase-bd
APOL1Other/UnknownnoApoL
LAMB2Other/UnknownnoEGF, LE_dom, Laminin_N
MYH9Scaffold/PPInoIQ_motif_EF-hand-BS, Myosin_head_motor_dom-like, Myosin_tail
NPHS1Antibody/ImmunoglobulinyesIg_sub2, Ig_sub, FN3_dom

Expression context

Cohort genes with no expression data: 0.

7 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)7
unknown0

Top tissues across cohort

TissueCohort genes
stromal cell of endometrium2
metanephric glomerulus1
renal glomerulus1
ventricular zone1
metanephros cortex1
pigmented layer of retina1
renal medulla1
nerve1
sural nerve1
tibial nerve1
gall bladder1
liver1
right lobe of liver1
apex of heart1
right lobe of thyroid gland1
ascending aorta1
thoracic aorta1
body of pancreas1
buccal mucosa cell1
vena cava1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
PLCE1271broadmarkerrenal glomerulus, metanephric glomerulus, ventricular zone
COL4A4187broadmarkerrenal medulla, metanephros cortex, pigmented layer of retina
INF2260ubiquitousmarkersural nerve, nerve, tibial nerve
APOL1252ubiquitousmarkergall bladder, right lobe of liver, liver
LAMB2268ubiquitousmarkerapex of heart, right lobe of thyroid gland, stromal cell of endometrium
MYH9279ubiquitousmarkerstromal cell of endometrium, ascending aorta, thoracic aorta
NPHS1147tissue_specificmarkerbuccal mucosa cell, body of pancreas, vena cava

Protein interactions among cohort

Intra-cohort edges: 12.

Hub genes (top 10 by interactor count)

SymbolInteractor count
MYH95,533
INF22,070
NPHS11,690
PLCE11,560
LAMB21,548
COL4A41,243
APOL11,216

Intra-cohort edges

ABSources
APOL1INF2string_interaction
APOL1MYH9string_interaction
APOL1NPHS1string_interaction
APOL1PLCE1string_interaction
COL4A4INF2string_interaction
COL4A4MYH9string_interaction
COL4A4NPHS1string_interaction
INF2MYH9intact, string_interaction
INF2NPHS1string_interaction
INF2PLCE1string_interaction
MYH9NPHS1string_interaction
NPHS1PLCE1string_interaction

Structural data

PDB: 6 · AlphaFold-only: 1 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
INF2Q27J8110
MYH9P355798
APOL1O147915
PLCE1Q9P2123
COL4A4P534202
NPHS1O605001

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
LAMB2P5526875.94

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 69. Enrichment computed across 7 evidence-associated genes (6 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 6 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Attachment of bacteria to epithelial cells2165.5×0.003COL4A4, LAMB2
Laminin interactions2126.9×0.003COL4A4, LAMB2
Non-integrin membrane-ECM interactions251.4×0.011COL4A4, LAMB2
ECM proteoglycans250.1×0.011COL4A4, LAMB2
Post-translational protein phosphorylation233.4×0.020APOL1, LAMB2
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)228.8×0.022APOL1, LAMB2
CD163 mediating an anti-inflammatory response1190.3×0.042MYH9
Scavenging of heme from plasma1146.4×0.042APOL1
Anchoring fibril formation1126.9×0.042COL4A4
Sema4D in semaphorin signaling1112.0×0.042MYH9
RHO GTPases activate CIT1100.2×0.042MYH9
RHO GTPases Activate ROCKs1100.2×0.042MYH9
MET promotes cell motility1100.2×0.042LAMB2
Fibronectin matrix formation195.2×0.042COL4A4
Crosslinking of collagen fibrils195.2×0.042COL4A4
Sema4D induced cell migration and growth-cone collapse195.2×0.042MYH9
Binding and Uptake of Ligands by Scavenger Receptors190.6×0.042APOL1
RHO GTPases activate PAKs190.6×0.042MYH9
Vesicle-mediated transport211.6×0.042APOL1, MYH9
Nephrin family interactions179.3×0.042NPHS1
Synthesis of IP3 and IP4 in the cytosol170.5×0.042PLCE1
Semaphorin interactions165.6×0.042MYH9
Anti-inflammatory response favouring Leishmania parasite infection165.6×0.042MYH9
Leishmania parasite growth and survival165.6×0.042MYH9
EPHA-mediated growth cone collapse163.4×0.042MYH9
MET activates PTK2 signaling163.4×0.042LAMB2
Parasite infection157.7×0.042MYH9
Leishmania phagocytosis157.7×0.042MYH9
RHO GTPases activate PKNs152.9×0.042MYH9
Signaling by MET152.9×0.042LAMB2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 7 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
glomerular basement membrane development2437.7×6e-04COL4A4, NPHS1
myoblast fusion2172.0×0.002MYH9, NPHS1
metanephric glomerular basement membrane development12407.4×0.007LAMB2
uropod organization11203.7×0.007MYH9
slit diaphragm assembly11203.7×0.007NPHS1
cortical granule exocytosis11203.7×0.007MYH9
metanephric podocyte development11203.7×0.007LAMB2
negative regulation of actin filament severing11203.7×0.007MYH9
positive regulation of protein processing in phagocytic vesicle11203.7×0.007MYH9
cytokinetic process1802.5×0.008MYH9
axon extension involved in regeneration1802.5×0.008LAMB2
regulation of plasma membrane repair1802.5×0.008MYH9
establishment of meiotic spindle localization1601.9×0.010MYH9
cytoplasmic actin-based contraction involved in cell motility1481.5×0.011MYH9
regulation of basement membrane organization1401.2×0.013LAMB2
meiotic spindle organization1343.9×0.014MYH9
obsolete cytolysis by host of symbiont cells1300.9×0.014APOL1
regulation of mitochondrial fission1300.9×0.014INF2
establishment of T cell polarity1267.5×0.014MYH9
diacylglycerol biosynthetic process1267.5×0.014PLCE1
radial glial cell differentiation1218.9×0.016LAMB2
podocyte development1218.9×0.016NPHS1
blood vessel endothelial cell migration1200.6×0.017MYH9
glomerulus development1185.2×0.017PLCE1
positive regulation of integrin-mediated signaling pathway1185.2×0.017LAMB2
astrocyte development1160.5×0.018LAMB2
positive regulation of muscle cell differentiation1160.5×0.018LAMB2
Schwann cell development1150.5×0.018LAMB2
lipoprotein metabolic process1133.8×0.020APOL1
regulated exocytosis1126.7×0.020MYH9

Therapeutics

Drugs indicated for this disease

3 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
ChlorothiazideApproved (phase 4)
ChlorthalidoneApproved (phase 4)
HydrochlorothiazideApproved (phase 4)
PentoxifyllinePhase 3 (in late-stage trials)
PrednisolonePhase 3 (in late-stage trials)
RamiprilPhase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Daratumumab, Dexamethasone, Felzartamab, Iptacopan, Lisinopril Anhydrous, Obinutuzumab, Olmesartan Medoxomil, Rituximab.

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 1 · Undrugged: 6

Druggability breadth: 5 of 7 evidence-associated genes (71%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
MYH912
PLCE100
COL4A400
INF200
APOL100
LAMB200
NPHS100

Drugs targeting cohort genes (top 30)

MoleculeMax phaseTargets in cohort
MOLIBRESIB2MYH9

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
MYH910Binding:10
APOL14Binding:4
INF21Binding:1

Cohort enzymes (BRENDA EC)

SymbolEC numbersNames
PLCE13.1.4.11phosphoinositide phospholipase C

Pharmacogenomics

Cohort genes with a PharmGKB record: 7; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

1 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

CompoundMax phaseCohort target (bioactivity)
MOLIBRESIB2MYH9

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved1MYH9
CDruggable family + PDB, no drug2PLCE1, NPHS1
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug4COL4A4, INF2, APOL1, LAMB2

Undrugged target profiles

6 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
COL4A40MYH9
APOL14MYH9
PLCE10—
INF21—
LAMB20—
NPHS10—

Clinical trials & evidence

Clinical trials

Clinical trials: 47.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified18
PHASE212
PHASE46
PHASE34
PHASE14
PHASE1/PHASE22
PHASE2/PHASE31

Top trials by phase / activity

NCTPhaseStatusTitle
NCT04662723PHASE4RECRUITINGMulticentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.
NCT00426348PHASE4COMPLETEDA Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy
NCT00862693PHASE4UNKNOWNCalcitriol in the Treatment of Immunoglobulin A Nephropathy
NCT02063100PHASE4UNKNOWNEfficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis
NCT02523768PHASE4TERMINATEDPrevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment
NCT04349683PHASE4UNKNOWNEfficacy and Safety of Jinshuibao for Patients With Chronic Kidney Disease Due to Glomerulonephritis
NCT06858319PHASE3RECRUITINGOpen-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
NCT00106561PHASE2/PHASE3COMPLETEDUsing the Drug Spironolactone to Test If It Reduces Protein Leakage From the Kidney
NCT00354198PHASE3TERMINATEDEfficacy of Pentoxifylline on Rapidly Progressive Glomerulonephritis
NCT00437463PHASE3COMPLETEDTreatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor
NCT05283057PHASE3COMPLETEDEmpagliflozin in Patients With Glomerulonephritis
NCT04663204PHASE2ACTIVE_NOT_RECRUITINGA Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy
NCT05517980PHASE2NOT_YET_RECRUITINGEfficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis
NCT06889948PHASE2RECRUITINGThe Effect of Daratumumab in Patients with Monoclonal Gammopathy of Renal Significance (MGRS) in Finland
NCT07096986PHASE2NOT_YET_RECRUITINGImpact of Dapagliflozin for the Regulation of Immunological Activity in Membranous Nephropathy
NCT00001457PHASE2COMPLETEDLamivudine for Chronic Hepatitis B
NCT00004990PHASE2COMPLETEDOnce-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis
NCT00914524PHASE2COMPLETEDStudy of Olmesartan Medoxomil (CS-866) in Patients With Chronic Glomerulonephritis or Diabetic Nephropathy
NCT01093157PHASE1/PHASE2COMPLETEDA Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy
NCT03832114PHASE2COMPLETEDStudy on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted
NCT04387448PHASE2TERMINATEDA Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
NCT04733040PHASE2COMPLETEDEfficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE)
NCT04846010PHASE1/PHASE2UNKNOWNRecovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2
NCT04950114PHASE2TERMINATEDAn Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases
NCT06835322PHASE2COMPLETEDEffect of Finerenone in Patients With Non-diabetic Glomerulonephritis
NCT00001676PHASE1COMPLETEDCyclophosphamide and Fludarabine to Treat Lupus Nephritis
NCT00345137PHASE1COMPLETEDEffects of Systemic NO-Inhibition on Renal Hemodynamics in Patiens With Polycystic Kidney Disease and Chronic Glomerulonephritis
NCT05174221PHASE1COMPLETEDA Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy
NCT05505955PHASE1COMPLETEDStudy of HRS-5965 in Healthy Subjects and Subjects With Renal Insufficiency
NCT05434325Not specifiedRECRUITINGTESTING -ON Post-Trial ObservatioNal Cohort Study
NCT06792448Not specifiedNOT_YET_RECRUITINGBiomarkers and Outcome Predictors of Pediatric Nephrotic Syndrome: A Genetic, Transcriptomic, and Secretome Multiomics Study
NCT07330362Not specifiedRECRUITINGThe Clinical Application of Artificial Intelligence Assisted Renal Biopsy Diagnosis System.
NCT07431931Not specifiedNOT_YET_RECRUITINGOptimizing Referral Pathways for Patients With Hematuria and Moderate-Severe Proteinuria
NCT00154661Not specifiedCOMPLETEDEvaluation of Clinical Efficacy of Pentoxifylline on Patients With Glomerulonephritis
NCT00983034Not specifiedCOMPLETEDThe Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy
NCT02700516Not specifiedCOMPLETEDRecurrent Glomerulonephritis After Renal Transplantation
NCT03126201Not specifiedCOMPLETEDPredictors of Disease Progression in Primary Focal Segmental Glomerulosclerosis
NCT03460054Not specifiedUNKNOWNThe Canadian Glomerulonephritis Registry and Translational Research Initiative
NCT03836144Not specifiedCOMPLETEDEffect of Urine Alkalinazation on Urinary Inflammatory Markers in Patients With Cystinuria
NCT04058951Not specifiedUNKNOWNPlant Versus Animal Dietary Protein and the Effect on Proteinuria

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
LOSARTAN42
POTASSIUM CITRATE ANHYDROUS42
BASILIXIMAB41
CALCITRIOL41
DAPAGLIFLOZIN PROPANEDIOL41
FINERENONE41
IPTACOPAN41
IRBESARTAN41
OLMESARTAN MEDOXOMIL41
PENTOXIFYLLINE41
PROBUCOL41
RAMIPRIL41
SPARSENTAN41
SPIRONOLACTONE41
VALSARTAN41
FELZARTAMAB31
TILARGININE31
ZIGAKIBART31
MEZAGITAMAB21
CHEMBL11562201
CHEMBL156222301
CHEMBL3045801

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 72

This page pulls from 72 datasets indexed by BioBTree:

alphafoldantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsclinvarctd_gene_interactiondbsnpdepmapdiamond_similaritydoidefoensemblentrezesm2_similarityfantom5_genefantom5_promotergardgenccgenerifgogtopdbgtopdb_interactiongwasgwas_studyhgncintactinterpromedgenmeshmimmondomondochildmondoparentncitorphanetpatent_compoundpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assayreactomerefseqrhearnacentralsctidscxa_expressionscxa_gene_experimentsignorstring_interactiontranscriptuberonufeatureumlsuniprot